The FDA has granted marketing authorization for a high-throughput genomic sequencer, Illumina's MiSeqDx, which will allow the development of innumerable new genome-based tests. Access to genomic data may transform research, clinical care, and patient engagement.
No takes yet. Share an insight, caveat, or question.
Collins et al. (2013) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: